Ligand Shares Slide After $550M Convertible Note Offering Announced
Ligand Pharmaceuticals shares fell in pre-market trading following the firm's disclosure of a private placement of $550 million in convertible senior notes due September 2031, with an underwriter option for an additional $82.5 million. The debt issuance, structured as a Rule 144A offering to qualified institutional buyers, raises both leverage and …